Compare Berkshire Hathaway Inc Class B (BRK.B) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Berkshire Hathaway Inc Class B vs Merck & Co., Inc. — how do they compare? Berkshire Hathaway Inc Class B trades at $491.24, while Merck & Co., Inc. trades at $123.94 (market cap $298.31B). The key difference: Merck & Co., Inc. pays a 2.82% dividend while Berkshire Hathaway Inc Class B pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Berkshire Hathaway Inc Class B nearer its low. Which is the better fit depends on your goals.
| BRK.B | MRK | |
|---|---|---|
Sector | Financials | Health |
52-Week High | $513.70 | $129.52 |
52-Week Low | $459.10 | $77.60 |
Market Cap | — | $298.31B |
Enterprise Value | — | $341.72B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Berkshire Hathaway Class B shares (BRK.B) trade at $496.79, up 0.63% on the day, with a bullish technical signal from moving averages. Analyst consensus is positive with 57% buy ratings. The stock's current price is near the pivot point of $497, with immediate resistance at $500 and support at $494.
The outlook remains favorable given strong institutional confidence and the company's diversified holdings, though risks include market volatility and economic cycles. Upside potential exists if the stock breaks above $500 resistance, supported by bullish momentum indicators.
Merck (MRK) trades at $124.03, up 0.4% today, with a bullish technical signal and strong institutional interest. Recent earnings beats and a 67.57% analyst buy rating support momentum. The company's acquisition of Terns Pharmaceuticals, announced on April 7, 2026, aims to bolster its oncology pipeline, while a dividend of $0.85 per share is scheduled for July 2026.
Outlook remains positive with a consensus price target of $137.30, though risks include rising debt levels and competitive pressures. Revenue growth is steady, but net income is projected to decline in 2026, highlighting execution challenges amid strategic expansions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Berkshire Hathaway Inc Class B
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
